Clinical Trial Update: Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the PET tracer [18F]MNI-777 as a marker of tau pathology in tauopathy subjects and healthy controls has been completed. The sponsor is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Frontotemporal Dementia
• Parkinson Disease
• Pick Disease
• Progressive Supranuclear Palsy
• Tauopathies
• Traumatic Encephalopathy

Drugs mentioned

• [18F]MNI-777 (MNI-777)

Snippet

Sponsor: Molecular NeuroImaging | Conditions: Alzheimer's Disease (AD), Parkinson's Disease (PD) | Phase 1 | Status: COMPLETED